Fulcrum Therapeutics Inc (NASDAQ:FULC)
| 8.39 Delayed Data As of May 24 |  +0.02 / +0.24%Today’s Change | 6.85 Today|||52-Week Range 33.10 | -52.57% Year-to-Date |
Latest FULC News | Press Releases
| Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus May 11 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 8.34 |
| Today’s open | 8.23 |
| Day’s range | 7.97 - 8.55 |
| Volume | 739,624 |
| Average volume (3 months) | 631,769 |
| Market cap | $348.0M |
Data as of 4:00pm ET, 05/24/2022
Growth & Valuation
| Earnings growth (last year) | +18.15% |
| Earnings growth (this year) | -14.11% |
| Earnings growth (next 5 years) | +12.20% |
| Revenue growth (last year) | +117.19% |
| P/E ratio | NM |
| Price/Sales | 32.64 |
| Price/Book | 1.66 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| EYPTEyePoint Pharmaceuti... | -0.53 | -5.50% |
| ZYMEZymeworks Inc | +0.01 | +0.17% |
| ---- | ||
| ABUSArbutus Biopharma Co... | -0.21 | -8.75% |
Data as of 4:00pm ET, 05/24/2022
Financials
| Next reporting date | August 29, 2022 |
| EPS forecast (this quarter) | -$0.66 |
| Annual revenue (last year) | $19.2M |
| Annual profit (last year) | -$80.8M |
| Net profit margin | -421.89% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
